Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema (HAE)
Angioedema

Interventions

DRUG: Lanadelumab 150 mg
DRUG: Lanadelumab 300 mg

Sponsor

Shire

Collaborators

[object Object]